The GLP-1 mania is in full swing now, as evidenced by Eli Lilly and Company (NYSE: LLY) smashing consensus expectations for its top-line and bottom-line metrics in Q3 2023, aided by the soaring demand for its Mounjaro weight loss drug. Eli Lilly and Company (NYSE: LLY) Earnings Release for the Third Quarter of 2023 For […]
Read full article at https://wccftech.com/glp-1-effect-eli-lilly-and-company-lly-smashes-q3-2023-revenue-expectations-on-weight-loss-drug-tailwind/
WccftechContinue reading/original-link]